StreetAlpha.app
Home › Stocks › ELVN

Enliven Therapeutics, Inc. (ELVN)

Healthcare
$46.53
▲ +0.26%
LAST CLOSE · NOV 20

Enliven Therapeutics develops small molecule drugs, led by an investigational kinase inhibitor for chronic myeloid leukemia. It last closed at $46.53 on Nov 20, up 0.26% on the day. The next earnings report for ELVN is expected around Tue, Mar 2, 2027, after the close. For the quarter ended Sep 2026, ELVN reported EPS of -$0.36. Over its last 8 reports the stock moved an average of 3.8% the session after earnings. Over the last 12 months ELVN insiders bought $0 of stock on the open market and sold $76.4M, according to SEC Form 4 filings.

AI Auto Pilots
Is ELVN in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold ELVN.

Key Stats

Last 12 months
Results
Net income
−$113.5M
EPS (diluted)
−$1.69
Free cash flow
−$66.4M
Valuation
Market cap
$3.4B
73.6M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$151.7M
At Sep 30
Shareholder equity
$876.9M
Shares outstanding
73.6M
At Oct 28
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$51.4M−$51.4MFY2021FY2022: −$37.7M−$37.7MFY2022FY2023: −$71.6M−$71.6MFY2023FY2024: −$89.0M−$89.0MFY2024FY2025: −$103.7M−$103.7MFY2025

From ELVN's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Mar 2
Estimated date · After the close
Reported EPS
-$0.36
Quarter ended Sep 2026
Year ago EPS
-$0.32
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.46Dec '24Mar 2025: -$0.57Mar '25Jun 2025: -$0.49Jun '25Sep 2025: -$0.32Sep '25Dec 2025: -$0.48Dec '25Mar 2026: -$0.38Mar '26Jun 2026: -$0.49Jun '26Sep 2026: -$0.36Sep '26Latest -$0.36
Revenue by quarter
Not enough quarters on file yet.
How ELVN moved after its last 8 reports
Average move the session after a report ±3.8%
Nov 5, 2026After the close+10.4%
Aug 5, 2026After the close+0.9%
May 7, 2026After the close+1.1%
Mar 3, 2026After the close+4.3%
Nov 12, 2025After the close−0.1%
Aug 13, 2025After the close−1.1%
May 14, 2025After the close−10.4%
Mar 13, 2025After the close+2.2%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on ELVNStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on ELVN
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on ELVN

Technical Analysis

ELVN · as of the Nov 20 close · updated each morning
Uptrend

The stock sits between its 20 and 50 day averages. It is 5% above its 200 day average, so the longer trend is still up. Momentum is fading (RSI 50). The nearest support is the Pivot S1 at $45.50, and the nearest resistance the Pivot at $46.67.

Short trendBullish
Long trendBullish
MomentumFading
StretchNormal
VolatilityNormal, 4.8%/day
Key levels
$62.3252 week high+33.9%
$50.77100 day average+9.1%
$47.69Pivot R1+2.5%
$47.36Swing high (Jun 12)+1.8%
$46.6820 day average+0.3%
$46.67Pivot+0.3%
$46.53Last close
$45.50Pivot S1−2.2%
$45.3450 day average−2.6%
$44.31200 day average−4.8%
$44.17Swing low (Sep 25)−5.1%
$14.7952 week low−68.2%
Indicators
RSI (14)50.43Middle of its rangeNeutral
MACD0.58Below its signal lineBearish
Stochastic27.6Middle of its rangeNeutral
ADX (14)21.5Weak trend
Williams %R-71.1Oversold below −80, overbought above −20Neutral
CCI (20)2.5Oversold below −100, overbought above 100Neutral
Rate of change−5.9%Change over 10 sessionsBearish
ATR (14)$2.23Typical daily range, 4.8% of price
MA 10Below
MA 20Below
MA 50Above
MA 100Below
MA 200Above
What happened before, for ELVN

What happened before

See how ELVN did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow ELVN usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How ELVN has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for ELVNHow many large options trades hit ELVN, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

Dark Pool

30D
Prints
Notional
Largest print
Loading…

ELVN Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲135 buying vs 85 selling
  • ▲Held by funds +3.8 pts
  • ▲Funds holding +5
  • ▲Superinvestors: 2 added, 1 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding218213+2.3%
In funds' top 101013−23.1%
Held by funds113.2%109.3%+3.8 pts
New / increased38 / 9761 / 86−8.2%
Reduced / sold out53 / 3248 / 20+25.0%
Put/call ratio0.010.00–
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See ELVN institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

ELVN Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$76.4M33 sales · 9 insiders
31% of the selling was under pre-arranged trading plans.
2025-12 sold $224K2026-01 sold $5.7M2026-02 sold $1.4M2026-03 sold $3.0M2026-04 sold $238K2026-05 sold $199K2026-06 sold $52.5M2026-07 sold $1.1M2026-08 sold $10.2M2026-09 sold $555K2026-10 sold $1.0M2026-11 sold $234KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Helen Louise CollinsChief Medical OfficerSale plan5,000$46.84$234K
Oct 19Helen Louise CollinsChief Medical OfficerSale plan5,000$38.47$192K
Oct 19Benjamin HohlCFOSale plan6,018$38.48$232K
Oct 1J. Scott GarlandDirectorSale13,000$46.67$607K
Sep 17Helen Louise CollinsChief Medical OfficerSale plan5,000$50.35$252K
Sep 17Benjamin HohlCFOSale plan6,018$50.35$303K
Every insider buy and sale for ELVN over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See ELVN insider trades →

From SEC Form 4 filings by ELVN's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether ELVN is in one of them and how their past ELVN trades turned out.

ELVN in the AI portfolios
Loading…

ELVN News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered ELVN in an article yet. Here's the latest on the wider market.

ELVN in the news

About Enliven Therapeutics

Enliven Therapeutics is a biopharmaceutical company based in Burlingame, California, that develops small molecule drugs. Its lead candidate, ELVN-001, is a kinase inhibitor being studied for chronic myeloid leukemia, a blood cancer, in patients whose disease has become resistant or intolerant to existing treatments. The company also runs research programs on other targeted therapies aimed at unmet medical needs.

Headquarters
Burlingame, CA